Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
Status:
Not yet recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to compare progression free survival between two available
systemic therapies - immunotherapy and tyrosine kinase inhibitors - after Therasphere®
(yttrium-90) treatment in adult patients with advanced hepatocellular carcinoma. The
immunotherapy consists of a standard-of-care treatment with Atezolizumab and Bevacizumab.
Treatment with tyrosine kinase inhibitors consists of standard-of-care Lenvatinib or
Cabozantinib.